0
Other Articles |

The Chemical Laboratory

JAMA. 1937;109(5):358. doi:10.1001/jama.1937.02780310036010.
Text Size: A A A
Published online

EXAMINATION OF CERTAIN AMERICAN BRANDS OF SULFANILAMIDE  The history of the introduction of para-amino-benzene sulfonamide in therapeutics was recounted in The Journal, January 2.It was apparently first introduced in the United States under the proprietary name "Prontylin." As this product was not, and could not be, protected by letters patent, and as other firms were privileged to make it, the Council on Pharmacy and Chemistry was approached for a nonproprietary name. The announcement of the term "Sulfanilamide" was made in The Journal, April 17. A report of the Council on Pharmacy and Chemistry on sulfanilamide appeared subsequently in The Journal, May 29.A number of firms have submitted brands of sulfanilamide for the Council's consideration with a view to acceptance and inclusion in New and Nonofficial Remedies. The Council in turn asked the A. M. A. Chemical Laboratory to examine theproduct and elaborate standards for identity and purity. At the time of this report the following firms had presented brands

Topics

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs